JLE

Innovations & Thérapeutiques en Oncologie

MENU

Cessation of tyrosine kinase inhibitors for chronic myeloid leukaemia: from remission without treatment to functional cure Volume 8, issue 6, November-December 2022

Figures


  • Figure 1.

  • Figure 2.

  • Figure 3.

Tables

Author
Institut Bergonié 229, cours de l’Argonne 33076 Bordeaux Cedex France <f.mahon@bordeaux.unicancer.fr>
* Tirés à part : F.-X. Mahon
Remerciements et autres mentions :
Financement : aucun.
Liens d’intérêts : l’auteur déclare ne pas avoir de lien d’intérêt.

Treatment discontinuation is considered one of the main goals of therapy for patients with chronic myeloid leukaemia. Several criteria are known to be necessary to consider discontinuation, but predictive factors to improve the chance of achieving treatment-free remission are not clear. Today, 30 to 40 % of newly diagnosed patients could be candidates for possible treatment cessation. The criteria for discontinuation include patients in chronic phase with a minimum duration of tyrosine kinase inhibitor therapy of five years, with a sustained deep molecular response for at least two years. The aim of research is to increase the number of candidates with a better understanding of treatment-free remission. In this current review, we highlight the results obtained in this new area. In some cases, the resulting questions go beyond current medical research as they are also linked to the health system and the definition of cure.